The board is considering studying eight name brand prescription drugs that treat a variety of diseases, including diabetes, HIV, and attention-deficit/hyperactivity disorder (ADHD).
Bill would allow the board to implement upper payment limits for prescription drug purchases and payer reimbursements if the state finds that certain drugs are ‘unaffordable.’
The Prescription Drug Affordability Board is working with a large list of ‘eligible’ prescription drugs that meet certain statutory or regulatory metrics that could indicate a drug is hard for Marylanders to afford.
Over the course of 2024, the board will gather data, manufacturer information and public testimonies that will inform its consideration of which drugs should undergo state cost reduction efforts.
New drugs will continue to be developed to treat rare diseases. But we must also look for ways to bring down costs, so everyone can afford the drugs they need.
Health care advocates believe the report supports their call to expand authority of a state board that aims to lower drug costs for Marylanders.
Health care-focused organizations across the state are hopeful that the 2024 legislative session will be a year that reins in health costs and allows…
A state board tasked with controlling prescription drug prices for Maryland workers said that they are likely to identify the first set of medications…
The board’s current authority only covers prescription drugs under state and local government health care plans.
Medications to treat diabetes and arthritis, common conditions for older people on Medicare, have seen major list price increases over the past 20 or…